Brazil registered its first mpox death in Rio de Janeiro on a Friday, involving a patient aged 40 to 49 with a pre-existing immunosuppressive condition, [O GLOBO reported].
State health authorities confirmed the fatality as local infection totals reached 382 cases in Rio de Janeiro, with two-thirds of those diagnoses appearing since September 13. Laboratory testing has confirmed roughly 49.5 percent of initial suspected notifications across the state, and 55 patients have required hospital admission. The average age of infected individuals is 33.8 years. The recent uptick in cases follows the local arrival of the clade 1b viral variant, a lineage that drove a severe outbreak across several African nations in 2024, including more than 78 mil casos e mil mortes in the Democratic Republic of the Congo, according to [CNN Brasil]. Health officials in São Paulo and Rio de Janeiro identified the new variant early this year, contributing to a national total exceeding 1,055 cases.
Across the country, São Paulo and Rio de Janeiro stand among the regions with the highest number of infections, holding 409 and 395 records respectively, figures that account for over 76% of the 1,055 total cases registered nationwide. The federal prosecutor Lucas Costa Almeida Dias said that the country had already registered 665 confirmed cases this year through November 4.
While international studies indicate that clade 1b carries higher transmissibility and a potential for more severe disease than the clade 2b strain seen during the 2022 global outbreak, medical experts emphasize that local surveillance remains critical to understanding how the virus behaves in the Brazilian population.
According to Bruno Tavares, an infectious disease specialist at Hospital Alemão Oswaldo Cruz, the increase in infections predominantly driven by the clade 1b variant differs from the scenario observed in Brazil in 2022, when infections by the clade 2b variant predominated.
Ministry of Health Distributes Mpox Vaccines to High-Risk Groups
In response to the rising case numbers, the Ministry of Health distributed more than duas mil doses da vacina against the Mpox to the municipal health administration in November. Immunization targets specific groups facing higher exposure risks or severe disease outcomes, including laboratory personnel working with Orthopoxviruses, immunocompromised individuals living with HIV/AIDS, and people who experienced direct medium- or high-risk contact with suspected or confirmed cases following health surveillance evaluations. The vaccination protocol requires two doses administered 28 days apart.
O Ministério Público Federal (MPF) instaurou um inquérito civil para apurar a possível omissão do Ministério da Saúde na aquisição e na distribuição de vacinas contra a MPox, considerando relatos de desabastecimento da rede pública em 2026.
Two days after vaccination was suspended in the Distrito Federal on November 3 due to a lack of stock, the Ministry of Health authorized the purchase of up to 20 mil doses for the strategic inventory of the Unified Health System (SUS).
Clinical Guidance and Prevention Measures
According to the World Health Organization (WHO), mpox is an infectious disease caused by a virus of the genus Orthopoxvirus. Health agencies advise the public to avoid direct physical contact with individuals showing suspicious infection signs, particularly skin or mucosal lesions. Common symptoms include rashes, mucosal lesions, fever, headaches, muscle aches, fatigue, and swollen lymph nodes, which typically persist for two to four weeks.
Medical management relies on supportive clinical care focused on symptom relief, complication prevention, and minimizing potential sequelae. Authorities recommend immediate medical evaluation for anyone identifying suspicious lesions on the genital, anal, or oral regions, even if fever is absent. Individuals should also suspend intimate contact and avoid sharing personal items such as towels and bedding when symptoms arise.
Worth a look